Apellis Pharmaceuticals, Inc. (APLS)
20.14
+0.28
(+1.41%)
USD |
NASDAQ |
Mar 05, 16:00
20.14
0.00 (0.00%)
After-Hours: 17:31
Apellis Pharmaceuticals Cash from Investing (Quarterly) : -0.108M for Dec. 31, 2025
Cash from Investing (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
Cash From Investing Definition
Cash from Investing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall investing activities of the company. A few examples of investing activities include net change in PP&E, and net divestitures.
Cash from Investing (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Investing (Quarterly) Benchmarks
| Ultragenyx Pharmaceutical, Inc. | -72.25M |
| Amneal Pharmaceuticals, Inc. | -45.45M |
| Alnylam Pharmaceuticals, Inc. | -37.17M |
| BioMarin Pharmaceutical, Inc. | -42.45M |
| Amicus Therapeutics, Inc. | -6.494M |
Cash from Investing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | -14.18M |
| Cash from Financing (Quarterly) | 1.259M |
| Free Cash Flow | 45.01M |
| Free Cash Flow Per Share (Quarterly) | -0.1128 |
| Free Cash Flow to Equity (Quarterly) | -13.27M |
| Free Cash Flow to Firm (Quarterly) | -3.379M |
| Free Cash Flow Yield | 1.76% |